Skip to main content
Figure 1 | Molecular Neurodegeneration

Figure 1

From: Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats

Figure 1

CSF and brain apoE levels were markedly increased with LXR agonist treatment. The levels of apoE in the CSF, soluble brain extracts, and plasma following systemic treatment with LXR agonists T1317 and GW3965 at 30 mpk for 3, 6, and 10 days were evaluated by Western blot analysis as described in Methods. A: Representative blots showing changes in apoE levels in the CSF of rats treated with vehicle or LXR agonists (left panel). Albumin was used as a loading control for all CSF blots. Densitometric analysis of Western blots for CSF apoE (right panel). B: DEA extracted soluble brain homogenates were prepared as described in Methods. Equal amounts of supernatant proteins were loaded per lane and apoJ was used as an additional loading control. Representative blots showing changes in apoE observed in the soluble brain fraction of rats treated with vehicle, T1317 and GW3965 (left panel). Densitometric analysis of Western blots for soluble brain apoE (right panel). C: Representative blots showing changes of apoE levels in the plasma of rats treated with vehicle or LXR agonists (left panel). Densitometric analysis of Western blots for plasma apoE (right panel). * p < 0.05 compared to vehicle treated controls by ANOVA, N = 4 per group.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326